文献速递胃肠外科围术期管理与 ERAS急腹症与外科感染

吡啶斯的明缩短结直肠术后肠麻痹持续时间(PyRICo-RCT):随机临床试验

Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial.
PubMed 文献 · Br J Surg · 2024-01-01

这项双盲随机对照试验在南澳大利亚两家医院纳入130例择期结直肠手术成人患者,随机分配至口服吡啶斯的明60 mg每日两次或安慰剂组。吡啶斯的明组胃肠功能恢复复合终点GI-2中位时间较安慰剂组缩短1天(2天 vs 3天,P=0.015),但术后肠麻痹发生率、住院时间和并发症无显著差异;作者结论认为需更大规模多中心研究确定最佳剂量。

要点

  • 吡啶斯的明组GI-2中位时间2天 vs 安慰剂组3天,缩短1天(P=0.015)。
  • 术后肠麻痹发生率17.2% vs 21.5%(P=0.532),无显著差异。
  • 住院时间中位5天 vs 5天(P=0.921),无显著差异。

核心结论

  • 吡啶斯的明使GI-2恢复更快且耐受性良好,但术后肠麻痹发生率、住院时间和并发症无显著差异。
  • 作者结论指出需更大规模多中心研究确定最佳剂量并评估吡啶斯的明在不同手术场景中的作用。

研究设计与样本

  • 双盲随机对照试验,在南澳大利亚两家医院纳入择期结直肠手术成人患者130例,吡啶斯的明组65例、安慰剂组65例。
  • 干预为口服吡啶斯的明60 mg或安慰剂每日两次,术后6小时开始至首次排便。
  • 主要结局为GI-2(首次排便时间与耐受口服饮食的复合指标),次要结局包括术后肠麻痹发生率(定义为GI-2大于4天)、住院时间和30天并发症,采用意向性治疗单因素分析。
  • 注册号ACTRN12621000530820。

主要发现

  • 130例患者平均(标准差)年龄58.4(16.4)岁,男性73例(56%)。
  • 吡啶斯的明组GI-2中位时间2天(四分位距1-3) vs 安慰剂组3天(四分位距2-4),吡啶斯的明组缩短1天(P=0.015)。
  • 术后肠麻痹发生率吡啶斯的明组17.2% vs 安慰剂组21.5%(P=0.532),无显著差异。
  • 住院时间中位吡啶斯的明组5天(四分位距4-8.75) vs 安慰剂组5天(四分位距4-7.5)(P=0.921),无显著差异。
  • 总体并发症、吻合口漏、心脏并发症或患者报告副作用均无显著差异。

局限性

  • 作者结论指出需更大规模多中心研究确定最佳剂量并评估吡啶斯的明在不同手术场景中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative ileus, driven by the cholinergic anti-inflammatory pathway, is the most common complication in patients undergoing colorectal surgery. By inhibiting acetylcholinesterase, pyridostigmine can potentially modulate the cholinergic anti-inflammatory pathway and accelerate gastrointestinal recovery. This study aimed to assess the efficacy of pyridostigmine in improving gastrointestinal recovery after colorectal surgery. METHODS: This double-blinded RCT enrolled adult patients undergoing elective colorectal surgery at two hospitals in South Australia. Patients were randomized to 60 mg oral pyridostigmine or placebo twice daily starting 6 h after surgery until the first passage of stool. The primary outcome was GI-2, a validated composite measure of time to first stool and tolerance of oral diet. Secondary outcomes included incidence of postoperative ileus (defined as GI-2 greater than 4 days), duration of hospital stay, and 30-day complications, evaluated by intention-to-treat univariate analysis. RESULTS: Of 130 patients recruited (mean(s.d.) age 58.4(16.4) years; 73 men, 56%), 65 were allocated to each arm. The median GI-2 was 1 day shorter with pyridostigmine compared with placebo (2 (i.q.r. 1-3) versus 3 (2-4) days; P = 0.015). However, there were no significant differences in postoperative ileus (17.2 versus 21.5%; P = 0.532) or duration of hospital stay (median 5 (i.q.r. 4-8.75) versus 5 (4-7.5) days; P = 0.921). Similarly, there were no significant differences in overall complications, anastomotic leak, cardiac complications, or patient-reported side effects. CONCLUSION: Pyridostigmine resulted in a quicker return of GI-2 and was well tolerated. Larger multicentre studies are required to determine the optimal dosing and evaluate the impact of pyridostigmine in different surgical settings. Registration number: ACTRN12621000530820 (https://anzctr.org.au).

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Traeger L, Bedrikovetski S, Fitzsimmons T, et al. Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial. Br J Surg. 2024. PMID: 38743864. doi:10.1093/bjs/znae121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。